Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Radiation Toxicity Treatment Market Outlook (2022 to 2029)

The global Radiation Toxicity Treatment Market was valued at US$ 3.55 Billion in 2021 and is expected to reach US$ 5.58 Billion by 2029, finds Future Market Insights (FMI) in a recent market survey.

Market Outlook:

Data Points Market Insights
Market Value 2022 USD 3.76 Billion
Market Value 2029 USD 5.58 Billion
CAGR 2022 to 2029 5.8%
Share of Top 5 Countries 57.4%
Key Players The key players in the radiation toxicity treatment market are Amgen, Jubilant Life Sciences, Siegfried Holdings, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV

Cancer is one of the leading causes of death around the world. The global prevalence of cancer is continuously increasing, increasing the demand for radiotherapy as a therapeutic option. Being exposed to radiation during radiotherapy causes radiation toxicity.

As per the previous decade's trend, around 50% of patients with liver cancer, colon cancer, pancreatic cancer, and prostate cancer were treated with radiotherapy. Radiotherapy not only destroys tumor cells, but it also destroys normal and healthy cells in the proximity of the tumor. This is the primary cause of radiation toxicity in 60% of individuals who receive radiotherapy. As a result, with the rising prevalence of cancer, the number of cases of radiation toxicity is also increasing around the world.

Significant investments in nuclear energy in some countries have been increased in recent years, resulting in more nuclear facilities, which has raised the risk of individuals being exposed to radiation. The radiotherapy coverage policies and reimbursements provide easy access to radiotherapy treatments.

Increased usage of positron emission tomography (PET) and single photon emission computed tomography (SPECT) scanners in hospitals and diagnostic centers increases radiation toxicity due to gamma radiation emission, which provides a potential growth opportunity for the radiation toxicity market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 5.74%
H1, 2022 Projected 5.79%
H1, 2022 Outlook 5.69%
BPS Change - H1, 2022 (O) – H1, 2022 (P) (-) 10 ↓
BPS Change – H1, 2022 (O) – H1, 2021 (-) 05 ↓

Regulatory compliances and clinical outcomes of treatment are dynamics that impact the market for radiation toxicity treatment. The market is subject to be influenced by macro, regulatory, and industrial factors. Developing radiation-drug combinations, and implementing non-ionic radiations for therapeutic use are key market developments.

According to FMI analysis, the radiation toxicity treatment market will show a decline in H1-2022 (O) growth rate as compared to H1-2021 by nearly 5 BPS. Additionally, a comparison of the growth rate for the projected H1-2022 and Outlook H1-2022 period also showed a dip of nearly 10 BPS.

Acute radiation damage, distal atrophy and necrosis, and radiation injury are factors that are leading toward a reduction in the BPS value for the radiation toxicity treatment market.

Development of treatment systems that use modulated beams of photons and protons to improve cancer outcomes by irradiating cancerous tissues in ways that lead to improved control of tumors and by reducing doses to healthy tissues to reduce treatment complications are two key factors that display a progressive approach towards growth for the overall radiation toxicity treatment market.

Conversely, other market segments are expected to perform objectively and achieve lucrative growth prospects in the next half of the projection period, owing to the clinical development of novel drug-radiotherapy.

Radiation Toxicity Treatment Market

2014 to 2021 Market Demand Outlook for Radiation Toxicity Treatment compared to 2022 to 2029 Forecast

Sales of the radiation toxicity treatment market grew at a CAGR of 4.9% between 2014 and 2021. In 2021, the global market of radiation toxicity treatment accounts for approx. 38% of the overall toxicology drug screening market which accounts for around US$ 9.4 Billion.

Radiation used in the treatment also damages the healthy cells present around cancer tumors in the human body, resulting in side effects such as dry mouth, mouth and gum sores, difficulty in swallowing, stiffness in the jaw, nausea, and others, after a duration ranging from days, months, to years.

For the prevention of damage to healthy cells, radiologists and dosimetrists are focusing on using software such as treatment planning software, radiation dose management, and others for providing the right amount of radiation doses to the patients at targeted locations, without harming the healthy cells around the tumor.

With technological evolution in the field of radiation, automation is successfully implemented in radiotherapy. Radiation therapy centers are increasingly using advanced software, such as treatment planning software, for developing a treatment plan for each beamline route for estimating the direction in which the therapy system will deliver radiotherapy to a patient hence, the demand for radiation toxicity treatment will increase and will drive the market.

The radiation toxicity treatment market is expected to grow in the future, as the healthcare profession continues to evolve as a result of the need to discover newer technologies to effectively diagnose any issue.

In addition, the market's growth is expected to be boosted by rising acceptance and quick expansion of new technologies in emerging economies throughout the forecast period. Leading companies are concentrating their efforts on the launch of new products as well as research and development.

Considering this, FMI expects the global radiation toxicity treatment to grow at a CAGR of 5.8% through 2029.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors Are Restraining the Demand for radiation toxicity treatment?

Lack of guidance regarding rare diseases such as acute radiation syndrome-specific research methodologies and identifying patients for a study, especially including very impaired or minimally impaired patients in research remains a challenge.

There also exist various legal and ethical issues to finding an adequate sample size for clinical research. Selecting appropriate outcomes and their measurement is difficult due to heterogeneity in treatment and the effect of various diseases in patients due to the absence of validated outcomes. Also, a lack of disease knowledge and diversity in terms of epidemiology, diagnosis, prognosis, and treatment affects the clinical trial design and planning.

In cases of rare diseases such as acute radiation syndrome, the patient–physician relationship may not fit with the traditional assumptions of medical care. The lack of disease-related expertise among healthcare professionals and psychological challenges associated with the diagnosis of an incurable disease may lead to improper treatment. Due to poor knowledge of rare diseases and limited therapeutic options of treatments, physicians may not act as competent technical experts who provide relevant information to patients.

To avoid this, disease specialists should be trained to deal with patients with rare diseases and they must learn to cope with assertive and well-informed expert patients. Educational associations and institutions in healthcare should encourage physicians to practice and improve their skills in this area.

This can prove to be a major restraining factor for the product segment of the radiation toxicity treatment market.

Country-wise Insights

What Makes the USA the Largest Market for radiation toxicity treatment?

In 2021, the USA dominated the North American market, with more than 91% of the market share. The United States of America has the largest market for radiation toxicity treatment. The market is driven by factors such as rising cancer incidence and mortality, the replacement of older therapies with newer ones, and the provision of reimbursements for radiation toxicity therapy, the United States of America is expected to reflect similar market trends over the projection timeframe. Furthermore, in the United States of America, the implementation of safety rules and policies, improved treatment outcomes of radiation toxicity therapy, and significant investments by key manufacturers in product development and distribution are boosting the radiation toxicity treatment market growth.

Why is Germany Considered a More Lucrative Market for Radiation Toxicity Treatment in Europe?

Germany dominated the European radiation toxicity treatment market and accounted for approx. 20.6% of the market share in 2021, owing to the increased use of PET and single-photon emission computed tomography scanning machines across various diagnostic centers. Furthermore, favorable health coverage policies and stringent regulations have boosted the market growth in the region.

While Europe is identified as a lucrative market, stakeholders are particularly eying the profits in East and South Asia. These regional markets are turning attractive with the increasing per capita healthcare expenditure and multiple government programs for integrated healthcare systems.

What are the Factors Fueling the Demand for Radiation Toxicity Treatment in China?

The radiation toxicity treatment market in China is projected to grow at a 10.4% CAGR in East Asia throughout the forecast period. Rising awareness about advanced radiation toxicity treatments, as well as improving healthcare infrastructure, are expected to fuel the growth of the China radiation toxicity treatment market throughout the forecast period. Furthermore, China's radiation toxicity treatment market is expected to rise at a faster rate by 2029 as a result of a strong focus on research and development in the region.

What Makes India an Emerging Market for Radiation Toxicity Treatment?

India is an emerging market for radiation toxicity treatment and accounts for the largest share of more than 48% of the South Asia radiation toxicity treatment market due to improving healthcare infrastructure, the large patient base for target diseases, and the growing presence of leading market players in the region to grab the advantage of the rising opportunities given in India. These are the main drivers of the radiation toxicity treatment market growth in this region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Why do Colony Stimulating Factors account for the highest share by Product?

Colony-stimulating factors are the leading segment and are expected to gain more than 78% of revenue share in 2021 owing to the increasing adoption of colony-stimulating factors (CSFs).

The management of febrile neutropenia in cancer patients has become increasingly important as chemotherapy doses have been increased and the variety of available treatment lines has grown. Colony-stimulating factors (CSFs) are growth hormones that prevent chemotherapy-induced neutropenia.

They include granulocyte-colony stimulating factors (G-CSF) and granulocyte macrophage-colony stimulating factors (GM-CSF). They are utilized in frail patients undergoing chemotherapy and patients undergoing highly haematotoxic programs.

Why does Acute Radiation Syndrome Contribute to the Highest Market Share by Indication?

Acute radiation syndrome is caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time. The acute radiation syndrome segment by indication is projected to account for 87.8% of the total market share in 2021 as acute radiation syndrome is highly progressive by nature and can affect patients in less than 24 hours of exposure to radiation.

Why does Ionizing Radiation Contribute to the highest market share by Type of Radiation?

Representing a whopping 89.6% share of the global market in 2021, ionizing radiation remains the highly preferred radiation toxicity treatment, particularly in developed countries. On the other side, it also continues to witness growing traction within developing regional markets. Under ionizing radiation, the gamma radiation method accounts for over 55.8% share, while alpha and beta radiation methods are observing significant adoption.

Which End User will be Most Preferred?

The hospital segment accounts for the highest share of over 88% in 2021 by the end user due to increasing adoption and increasing footfalls to seek effective radiation toxicity treatment at hospitals, availability of advanced devices, and the presence of qualified medical personnel in the hospital.

Competitive Landscape

The global radiation toxicity treatment market is highly consolidated. Leading players in the radiation toxicity treatment market are also emphasizing collaboration with distributors or local manufacturers to enhance their distribution channels in emerging economies.

For instance, In September 2020, the AI-Rad Companion Organs RT, the latest AI-Rad Companion artificial intelligence-based software assistant from Siemens Healthineers, received FDA approval. As part of the radiation therapy planning workflow, AI-Rad Companion Organs RT uses deep-learning AI algorithms to autonomously outline organs at risk (OARs) on computed tomography (CT) images, facilitating precision medicine.

In May 2018, Partner Therapeutics signed a distribution agreement with Tanner Pharma Group for the distribution of Leukine in areas outside the USA and Canada.

In January 2017, Jubilant Life Sciences Limited signed a long-term contract with distribution networks in the USA for the supply of products used for diagnostic and therapeutic products with Montreal Canada (JDI).

Scope of the Report

Attribute Details
Forecast Period 2022 to 2029
Historical Data Available for 2014 to 2021
Market Analysis USD Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia and  Pacific, East Asia, and Middle East & Africa
Key Countries Covered USA, Canada,  Brazil,  Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain,  Benelux, Russia, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Thailand, Indonesia, Australia and New Zealand, Egypt, Turkey, South Africa, North Africa, and GCC Countries
Key Segments Covered Product, Indication, End User, Radiation and Region
Key Companies Profiled
  • Amgen
  • Partner Therapeutics, Inc.
  • Novartis AG
  • Mylan NV
  • Coherus BioSciences Inc.
  • Jubilant Life Sciences
  • Siegfried Holdings
  • Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
  • Recipharm AB
  • Mission Pharmacal Company
Report Coverage Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing Available upon Request

Radiation toxicity treatment Market by Category

By Product:

  • Colony Stimulating Factors
  • Potassium Iodide
  • Prussian Blue
  • Diethylenetriamine Pentaacetic Acid
  • Others

By Indication:

  •  Acute Radiation Syndrome
    • Bone Marrow Syndrome (Hematopoietic)
    • Gastrointestinal Syndrome (GI)
    • Cardiovascular (CV)
  • Chronic Radiation Syndrome

By Radiation Type:

  • Ionizing Radiation
    • Alpha Radiation
    • Beta Radiation
    • Gamma Radiation
  • Non-ionizing Radiation

By End-User:

  • Hospitals
    • Government Hospitals
    • Private Hospitals
  • Research & Academic Institutes
    • Government Research and Academic Institutes
    • Private Research and Academic Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How much is the radiation toxicity treatment Market currently worth?

The global radiation toxicity treatment market is worth US$ 3.55 Billion in 2021 and is set to expand 1.5X over the next 7 years.

What is the sales forecast for radiation toxicity treatment through 2029?

The radiation toxicity treatment market is expected to reach US$ 5.58 Billion by the end of 2029, with sales revenue expected to grow at a 5.8% CAGR.

What are the factors driving the demand outlook of the global radiation toxicity treatment?

An increasing number of PET and SPECT scanners, continuous drug approvals for radiation toxicity treatment, and the increasing burden of cancer worldwide are the factors driving the demand outlook of the global radiation toxicity market.

Which is the largest market for radiation toxicity treatment?

North America currently holds the largest market share of 38.0% in 2021 in the radiation toxicity treatment market globally.

What are the top 5 countries driving demand for radiation toxicity treatment?

The USA, Japan, China, Germany, and India are the top 5 countries that are driving the demand for the radiation toxicity treatment market.

Which are the leading companies in radiation toxicity treatment market?

Amgen, Partner Therapeutics, Inc., Novartis AG, Mylan NV, Coherus BioSciences Inc, Jubilant Life Sciences, Siegfried Holdings, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB and Mission Pharmacal Company are the leading players in the market.

What are the key market statistics in Japan?

Japan’s market is expected to exhibit healthy growth of 6.9% CAGR during the forecast period.

At what percentage radiation toxicity treatment market is expected to register growth in Europe?

The demand for radiation toxicity treatment is expected to register a growth rate of 4.7% during the forecast period in the European market.

Table of Content

1. Executive Summary | Radiation Toxicity Treatment Market

    1.1. Global Market Outlook

    1.2. Supply-side Trends

    1.3. Demand-side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Dynamics

    3.1. Macro-Economic Factors

    3.2. Drivers

        3.2.1. Supply Side Drivers

        3.2.2. Demand Side Drivers

    3.3. Restraints

    3.4. Opportunities

4. Key Inclusion

    4.1. FDA-Approved Drugs

    4.2. Pipeline Assessment

    4.3. Therapeutic Efficacy and Treatment Metrics

    4.4. Predisposing Factors

5. Global Market Value Analysis 2014 to 2021 and Forecast, 2022 to 2029

    5.1. Historical Market Value (US$ Million) Analysis, 2014 to 2021 

    5.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2029

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Product

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Million) Analysis by Product, 2014 to 2021 

    6.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Product, 2022 to 2029

        6.3.1. Colony Stimulating Factors

        6.3.2. Prussian Blue

        6.3.3. Diethylenetriamine Pentaacetic Acid

        6.3.4. Potassium Iodide

        6.3.5. Others

    6.4. Market Attractiveness Analysis by Product

7. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Indication

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Million) Analysis by Indication, 2014 to 2021 

    7.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Indication, 2022 to 2029

        7.3.1. Acute Radiation Syndrome (ARS)

            7.3.1.1. Bone Marrow Syndrome (Hematopoietic)

            7.3.1.2. Gastrointestinal Syndrome (GI)

            7.3.1.3. Cardiovascular (CV)

            7.3.1.4. Central Nervous System (CNS) Syndrome

        7.3.2. Chronic Radiation Syndrome

    7.4. Market Attractiveness Analysis by Indication

8. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Radiation

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis by Radiation, 2014 to 2021 

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Radiation, 2022 to 2029

        8.3.1. Acute Radiation Syndrome (ARS)

            8.3.1.1. Bone Marrow Syndrome (Hematopoietic)

            8.3.1.2. Gastrointestinal Syndrome (GI)

            8.3.1.3. Cardiovascular (CV)

            8.3.1.4. Central Nervous System (CNS) Syndrome

        8.3.2. Chronic Radiation Syndrome

    8.4. Market Attractiveness Analysis by Radiation

9. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis by End User, 2014 to 2021 

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2022 to 2029

        9.3.1. Hospitals

            9.3.1.1. Government Hospitals

            9.3.1.2. Private Hospitals

        9.3.2. Research & Academic Institutes

            9.3.2.1. Government Research and Academic Institutes

            9.3.2.2. Private Research and Academic Institutes

    9.4. Market Attractiveness Analysis by End User

10. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Million) Analysis by Region, 2014 to 2021 

    10.3. Current Market Size (US$ Million) Analysis and Forecast by Region, 2022 to 2029

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East & Africa

    10.4. Market Attractiveness Analysis by Region

11. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    11.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        11.3.1. By Country

            11.3.1.1. USA

            11.3.1.2. Canada

        11.3.2. By Product

        11.3.3. By Indication

        11.3.4. By Radiation

        11.3.5. By End User

    11.4. Market Attractiveness Analysis

    11.5. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    12.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Product

        12.3.3. By Indication

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

    12.5. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    13.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. United Kingdom

            13.3.1.3. France

            13.3.1.4. Italy

            13.3.1.5. Spain

            13.3.1.6. Rest of Europe

        13.3.2. By Product

        13.3.3. By Indication

        13.3.4. By Radiation

        13.3.5. By End User

    13.4. Market Attractiveness Analysis

    13.5. Drivers and Restraints - Impact Analysis

14. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    14.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Product

        14.3.3. By Indication

        14.3.4. By Radiation

        14.3.5. By End User

    14.4. Market Attractiveness Analysis

    14.5. Drivers and Restraints - Impact Analysis

15. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    15.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Thailand

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Asia

        15.3.2. By Product

        15.3.3. By Indication

        15.3.4. By Radiation

        15.3.5. By End User

    15.4. Market Attractiveness Analysis

    15.5. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    16.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Product

        16.3.3. By Indication

        16.3.4. By Radiation

        16.3.5. By End User

    16.4. Market Attractiveness Analysis

    16.5. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2021 

    17.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Turkey

            17.3.1.4. Rest of Middle East and Africa(MEA)

        17.3.2. By Product

        17.3.3. By Indication

        17.3.4. By Radiation

        17.3.5. By End User

    17.4. Market Attractiveness Analysis

    17.5. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

    18.1. Tier Structure Analysis

    18.2. Market Concentration

    18.3. Company Share Analysis

    18.4. Company Footprint Analysis

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Deep Dive

        19.2.1. Amgen

            19.2.1.1. Company Overview

            19.2.1.2. Analyst Commentary

            19.2.1.3. Product Overview

            19.2.1.4. Financial Analysis

            19.2.1.5. Key Developments

            19.2.1.6. Strategy Overview

        19.2.2. Partner Therapeutics, Inc.

            19.2.2.1. Company Overview

            19.2.2.2. Analyst Commentary

            19.2.2.3. Product Overview

            19.2.2.4. Financial Analysis

            19.2.2.5. Key Developments

            19.2.2.6. Strategy Overview

        19.2.3. Novartis AG

            19.2.3.1. Company Overview

            19.2.3.2. Analyst Commentary

            19.2.3.3. Product Overview

            19.2.3.4. Financial Analysis

            19.2.3.5. Key Developments

            19.2.3.6. Strategy Overview

        19.2.4. Mylan NV

            19.2.4.1. Company Overview

            19.2.4.2. Analyst Commentary

            19.2.4.3. Product Overview

            19.2.4.4. Financial Analysis

            19.2.4.5. Key Developments

            19.2.4.6. Strategy Overview

        19.2.5. Coherus BioSciences Inc

            19.2.5.1. Company Overview

            19.2.5.2. Analyst Commentary

            19.2.5.3. Product Overview

            19.2.5.4. Financial Analysis

            19.2.5.5. Key Developments

            19.2.5.6. Strategy Overview

        19.2.6. Jubilant Life Sciences

            19.2.6.1. Company Overview

            19.2.6.2. Analyst Commentary

            19.2.6.3. Product Overview

            19.2.6.4. Financial Analysis

            19.2.6.5. Key Developments

            19.2.6.6. Strategy Overview

        19.2.7. Siegfried Holdings

            19.2.7.1. Company Overview

            19.2.7.2. Analyst Commentary

            19.2.7.3. Product Overview

            19.2.7.4. Financial Analysis

            19.2.7.5. Key Developments

            19.2.7.6. Strategy Overview

        19.2.8. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG

            19.2.8.1. Company Overview

            19.2.8.2. Analyst Commentary

            19.2.8.3. Product Overview

            19.2.8.4. Financial Analysis

            19.2.8.5. Key Developments

            19.2.8.6. Strategy Overview

        19.2.9. Recipharm AB

            19.2.9.1. Company Overview

            19.2.9.2. Analyst Commentary

            19.2.9.3. Product Overview

            19.2.9.4. Financial Analysis

            19.2.9.5. Key Developments

            19.2.9.6. Strategy Overview

        19.2.10. Mission Pharmacal Company

            19.2.10.1. Company Overview

            19.2.10.2. Analyst Commentary

            19.2.10.3. Product Overview

            19.2.10.4. Financial Analysis

            19.2.10.5. Key Developments

            19.2.10.6. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Radiotherapy Patient Positioning Accessories Market

Published : March 2023

Healthcare

Radiation-Induced Myelosuppression Treatment Market

Published : July 2022

Healthcare

Superficial Radiation Therapy System Market

Published : June 2022

Healthcare

Radiation Toxicity Treatment Market

Published : June 2022

Explore Healthcare Insights

View Reports

Radiation Toxicity Treatment Market